Dimethyl Fumarate, registered for the treatment of relapsing forms of Multiple Sclerosis and psoriasis, exerts inhibiting effects against inflammation, neurodegeneration and toxic OS through activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) transcriptional pathway as well as interaction with the anti-inflammatory hydroxycarboxylic acid receptor 2 (HCAR2) (Kourakis et al., 2020). Here, NFE2L2 is linked to psoriasis.